-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $40

Benzinga·11/11/2026 14:01:08
Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $55 to $40.